- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06351475
Eficácia do uso intraoperatório de albumina a 20% combinada com lactato de Ringer versus lactato de Ringer durante cirurgia citorredutiva com quimioterapia intraperitoneal hipertérmica: protocolo para um ensaio clínico randomizado aberto (ALBUCHIP)
Avaliação da eficácia da Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate comparada com Ringer Lactate Seul Chez Les Patientes opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique
Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.
Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.
Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Intervention
- 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
- Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28
Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.
Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jérôme Lambert, Pr
- Número de telefone: +33 142499742
- E-mail: jerome.lambert@u-paris.fr
Estude backup de contato
- Nome: Arthur Moreau, Dr
- Número de telefone: +33 142499394
- E-mail: arthur.moreau@aphp.fr
Locais de estudo
-
-
-
Lyon, França
- Recrutamento
- Hôpital Lyon Sud Pierre Bénite
-
Contato:
- Anne Li
- Número de telefone: +33 04 78 86 14 76
- E-mail: anne.li@chu-lyon.fr
-
Montpellier, França
- Recrutamento
- Institut régional du Cancer de Montpellier
-
Contato:
- Lana Zoric
- Número de telefone: +33 467618538
- E-mail: Lana.Zoric@icm.unicancer.fr
-
Paris, França, 75013
- Recrutamento
- La Pitié Salpetriere hospital
-
Contato:
- Alexandre Sitbon
- Número de telefone: +33 184827399
- E-mail: alexandre.sitbon@aphp.fr
-
Paris, França
- Recrutamento
- Lariboisière hospital
-
Contato:
- Nathalie Poirier
- Número de telefone: +33 1 49 95 68 43
- E-mail: nathalie.poirier@aphp.fr
-
Paris, França
- Recrutamento
- Saint Louis hospital
-
Contato:
- Arthur Moreau
- Número de telefone: +33 142499394
- E-mail: arthur.moreau@aphp.fr
-
Reims, França
- Recrutamento
- Robert Debré hospital
-
Contato:
- Ezechiel Bankole
- Número de telefone: +33 326788801
- E-mail: ebankole@chu-reims.fr
-
Strasbourg, França
- Recrutamento
- Hôpital Hautepierre / UIC ARMO
-
Contato:
- Valentina FAITOT
- Número de telefone: +33 388116768
- E-mail: valentina.faitot@chru-strasbourg.fr
-
Villejuif, França
- Recrutamento
- Gustave Roussy Institute
-
Contato:
- Stéphanie Suria
- Número de telefone: +33 142114437
- E-mail: Stephanie.SURIA@gustaveroussy.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male and female patients aged 18 years old and older
- Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
- Patient volunteer for the study and provided written informed consent
- Patient affiliated to the French Health Insurance
Exclusion Criteria:
- Adults >75 years old
- Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
- Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
- Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
- History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
- Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
- Significant ascites with preoperative respiratory repercussions
- Uncontrolled diabetes (HbA1c > 8.5%)
- Allergy to exogenous human albumin and its excipients.
- Contraindication to the administration of Ringer's lactate (history of allergy)
- Hyperkalemia > 6.0 mmol/L
- Hypercalcemia (total calcium > 2.60 mmol/L)
- Chronic use of digitalis and hyperkalemic diuretics
- Pregnancy, breastfeeding
- Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
- Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
- Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
- Patient deprived of liberty
- Patient under guardianship or curatorship
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 20% Albumin + Ringer Lactate group
Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
|
Comparador Ativo: Control group
Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned. |
Ringer lactate |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Comprehensive Complication Index score
Prazo: At day 28
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 28
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Volume de fluidoterapia intraoperatória e pós-operatória
Prazo: 48 horas após a cirurgia
|
48 horas após a cirurgia
|
|
|
Incidência cumulativa de complicações pós-operatórias cirúrgicas
Prazo: Até dia 28
|
Até dia 28
|
|
|
Número de dias vivos fora da unidade de terapia intensiva
Prazo: Até dia 28
|
Até dia 28
|
|
|
Número de dias vivos fora do hospital
Prazo: Até dia 28
|
Até dia 28
|
|
|
Incidência de complicações infecciosas
Prazo: Até ao dia 28
|
Até ao dia 28
|
|
|
Incidência de complicações médicas
Prazo: Até ao dia 28
|
Até ao dia 28
|
|
|
Incidência cumulativa de morte em unidade de cuidados intensivos
Prazo: Até ao dia 28
|
Até ao dia 28
|
|
|
Incidência cumulativa de morte no hospital
Prazo: Até ao dia 28
|
Até ao dia 28
|
|
|
Número de dias sob vasopressores
Prazo: Até ao dia 28
|
Até ao dia 28
|
|
|
Proporção de doentes com complicações alérgicas à albumina
Prazo: No dia 133
|
No dia 133
|
|
|
Comprehensive Complication Index score
Prazo: At day 7
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 7
|
|
Number of days under mechanical ventilation outside the operating room
Prazo: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Number of days under renal replacement therapy
Prazo: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Sequential organ failure assessment (SOFA) score variation
Prazo: 48 hours after surgery
|
Between pre operative period and 48h after surgery |
48 hours after surgery
|
|
SOFA score
Prazo: At day 28
|
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function |
At day 28
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- APHP230864
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .